IEEE Spectrum on MSN
Why the most accurate glucose monitors are failing some users
In late November Abbott—one of Dexcom’s main competitors— recalled some of its CGMs due to inaccurate low glucose readings.
The US FDA has cleared a new “basal insulin dose optimizer” function for the Dexcom G7 15-day continuous glucose monitor (CGM), which is set to launch separately on December 1, 2025. The “Smart Basal” ...
Dexcom Smart Basal is designed to make basal insulin initiation and management simpler and more personalized for users and their healthcare providers. * Dexcom Smart Basal is FDA cleared and now the ...
Dexcom has obtained an FDA clearance for its basal insulin dosing optimizing program, designed for adults with Type 2 diabetes using its continuous glucose monitors. The company said its Smart Basal ...
DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for people over the age of 18 with diabetes will ...
Morgan Stanley analyst Patrick Wood upgraded the stock to Overweight from Equal Weight on Tuesday, citing a favorable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback